Search hospitals > Nevada > Reno
Radiation Oncology Associates
Claim this profileReno, Nevada 89509
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Tumors
Conducts research for Breast Cancer
Conducts research for Adenocarcinoma
137 reported clinical trials
2 medical researchers
Summary
Radiation Oncology Associates is a medical facility located in Reno, Nevada. This center is recognized for care of Cancer, Lung Cancer, Tumors, Breast Cancer, Adenocarcinoma and other specialties. Radiation Oncology Associates is involved with conducting 137 clinical trials across 355 conditions. There are 2 research doctors associated with this hospital, such as John A. Ellerton and Alan K. Ikeda.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage I
2Lung Cancer
Global LeaderStage IV
Stage II
Stage I
Top PIs
John A. EllertonOptumCare Cancer Care at Fort Apache4 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
148 reported clinical trials
226 drugs studied
Alan K. IkedaAlliance for Childhood Diseases/Cure 4 the Kids Foundation7 years of reported clinical research
Expert in Tumors
Expert in Leukemia
52 reported clinical trials
109 drugs studied
Clinical Trials running at Radiation Oncology Associates
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Bladder Cancer
Cancer
Bladder Carcinoma
Gastric Cancer
Renal Cell Carcinoma
Esophageal Cancer
Anal Cancer
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Questionnaire Choice
for Cancer Data Quality
The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.
Recruiting1 award N/A11 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Radiation Oncology Associates?
Radiation Oncology Associates is a medical facility located in Reno, Nevada. This center is recognized for care of Cancer, Lung Cancer, Tumors, Breast Cancer, Adenocarcinoma and other specialties. Radiation Oncology Associates is involved with conducting 137 clinical trials across 355 conditions. There are 2 research doctors associated with this hospital, such as John A. Ellerton and Alan K. Ikeda.